Aptamer discovery automation is revolutionizing the development of precision diagnostics for oncology. Recent research published in ACS Nano introduces DREAMbot, a microfluidic-integrated robotic platform. This system streamlines the evolution of aptamers against complex exosome targets. Exosomes, or extracellular vesicles (EVs), serve as critical biomarkers in liquid biopsies. However, their extreme heterogeneity and small size often make traditional antibody-based recognition difficult. DREAMbot solves this by automating the systematic evolution of ligands by exponential enrichment (SELEX) process with minimal human intervention.

Streamlining Aptamer Discovery Automation via DREAMbot

The DREAMbot platform integrates programmable robotics with advanced microfluidic techniques. It specifically employs deterministic lateral displacement sorting and lipid-assisted magnetic isolation. These technologies allow for the automated purification and recovery of aptamers from cell-derived vesicles and molecular contaminants. Consequently, the robotic-microfluidic workflow reduces the hands-on burden of manual SELEX. It maintains high enrichment fidelity while providing a practical framework for diagnostic research.

Clinical Significance for Hepatocellular Carcinoma

The study specifically targeted GPC3-positive exosomes, which are vital markers for hepatocellular carcinoma (HCC). DREAMbot identified aptamers with nanomolar dissociation constants and high specificity for these biomarkers. For clinicians in India, where HCC remains a significant challenge due to high viral hepatitis rates, this automation offers a faster path toward reliable diagnostic tools. Furthermore, the modular architecture of DREAMbot makes it accessible for broader applications in various cancer types. Therefore, this advancement supports the growth of personalized medicine and real-time disease monitoring.

Frequently Asked Questions

How does DREAMbot differ from traditional SELEX?

Unlike manual SELEX, which is labor-intensive and prone to human error, DREAMbot automates the entire multiround selection process. It uses microfluidics and robotics to ensure consistent results while significantly reducing hands-on time for laboratory staff.

Why is GPC3 a relevant target for this platform?

GPC3 (Glypican-3) is a cell-surface protein overexpressed in hepatocellular carcinoma. Detecting GPC3-positive exosomes in blood samples allows for potentially earlier and more accurate diagnosis of liver cancer compared to traditional markers like alpha-fetoprotein (AFP).

Can this technology be used for other types of cancer?

Yes. The modular nature of the DREAMbot platform allows researchers to target different exosome types. Consequently, it serves as a versatile framework for discovering aptamers for a wide range of oncological and inflammatory conditions.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Liu B et al. Deterministic Evolution of Aptamers via a Microfluidic-Integrated Robotic Platform Using Complex Exosomes as Targets. ACS Nano. 2026 Feb 07. doi: 10.1021/acsnano.5c14524. PMID: 41653459.

Xu H et al. Recent progress in aptamer-based microfluidics for the detection of circulating tumor cells and extracellular vesicles. PMC. 2024.

Zhu J et al. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. PMC. 2023.